Zimmer Biomet (NYSE:ZBH) updated its FY21 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $7.60-$8.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.72. The company issued revenue guidance of $8.01-$8.22 billion, compared to the consensus revenue estimate of $7.96 billion.Zimmer Biomet also updated its FY 2021 guidance to 7.600-8.000 EPS.
A number of research analysts have recently commented on ZBH shares. BTIG Research lifted their price objective on shares of Zimmer Biomet from $160.00 to $173.00 and gave the company a buy rating in a research report on Monday, January 25th. JMP Securities boosted their price objective on Zimmer Biomet from $165.00 to $180.00 and gave the stock an outperform rating in a report on Wednesday, January 27th. TheStreet cut Zimmer Biomet from a b- rating to a c+ rating in a report on Monday, March 29th. Raymond James increased their price objective on Zimmer Biomet from $170.00 to $187.00 and gave the stock a strong-buy rating in a research report on Monday, February 8th. Finally, Zacks Investment Research cut shares of Zimmer Biomet from a hold rating to a sell rating and set a $167.00 target price for the company. in a research report on Wednesday, February 10th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, sixteen have assigned a buy rating and three have assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $167.83.
NYSE:ZBH traded down $5.01 during trading hours on Tuesday, hitting $172.93. The company’s stock had a trading volume of 1,754,512 shares, compared to its average volume of 1,214,433. Zimmer Biomet has a twelve month low of $108.78 and a twelve month high of $180.36. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.18 and a quick ratio of 1.02. The stock has a fifty day simple moving average of $167.30 and a 200-day simple moving average of $156.15. The company has a market capitalization of $36.02 billion, a P/E ratio of 1,080.88, a PEG ratio of 4.32 and a beta of 1.34.
The business also recently declared a quarterly dividend, which was paid on Friday, April 30th. Stockholders of record on Monday, March 29th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Friday, March 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.56%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.20%.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.
Read More: What is a balanced fund?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.